Insider Screener
Real-time Form 4 Filtering Engine
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry (by SEC) | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-25 21:15 | 2026-03-23 | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | Officer; Chief Operating Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $78.02 | 115,977 | $9,048,294 | 61,202 | -65.5% |
| 2026-03-25 20:36 | 2026-03-23 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | Director | Biological Products, (No Diagnostic Substances) | SALE | $3.25 | 40,000 | $130,000 | 906,556 | -4.2% |
| 2026-03-25 20:30 | 2025-04-14 | PYXS | Pyxis Oncology, Inc. | HUMPHREY RACHEL | Director | Pharmaceutical Preparations | SALE | $1.03 | 15,496 | $15,917 | 81,309 | -16.0% |
| 2026-03-25 20:30 | 2026-03-23 | LQDA | Liquidia Corp | Moomaw Scott | Officer; Chief Commercial Officer | Pharmaceutical Preparations | OPT+S | $36.79 | 18,314 | $673,752 | 187,640 | -8.9% |
| 2026-03-25 20:31 | 2026-03-24 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Pharmaceutical Preparations | OPT+S | $529.36 | 9,500 | $5,028,919 | 40,513 | -19.0% |
| 2026-03-25 20:05 | 2026-03-23 | VCEL | Vericel Corp | Hagen Heidi | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $32.41 | 15,000 | $486,150 | 31,850 | -32.0% |
| 2026-03-25 15:13 | 2026-03-23 | LGND | LIGAND PHARMACEUTICALS INC | Sabba Stephen L | Director | Pharmaceutical Preparations | SALE | $207.87 | 1,000 | $207,873 | 32,793 | -3.0% |
| 2026-03-24 20:02 | 2026-03-20 | BCRX | BIOCRYST PHARMACEUTICALS INC | HEGGIE THERESA | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $10.11 | 49,933 | $504,823 | 65,352 | -43.3% |
| 2026-03-24 20:35 | 2026-03-23 | VIR | Vir Biotechnology, Inc. | Sabatini Brent | Officer; SVP, Chief Accounting Officer | Biological Products, (No Diagnostic Substances) | SALE | $9.12 | 7,711 | $70,324 | 61,902 | -11.1% |
| 2026-03-24 20:19 | 2026-03-20 | STOK | Stoke Therapeutics, Inc. | Allan Jonathan | Officer; GENERAL COUNSEL & CORP SEC | Pharmaceutical Preparations | SALE | $33.69 | 9,293 | $313,038 | 19,543 | -32.2% |
| 2026-03-24 20:05 | 2026-03-24 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% owner | Pharmaceutical Preparations | BUY | $72.00 | 39,665 | $2,855,880 | 15,000 | +100.0% |
| 2026-03-24 20:05 | 2026-03-20 | TWST | Twist Bioscience Corp | Cho Dennis | Officer; See Remarks | Biological Products, (No Diagnostic Substances) | SALE | $43.79 | 354 | $15,500 | 137,903 | -0.3% |
| 2026-03-24 20:05 | 2026-03-20 | TWST | Twist Bioscience Corp | Green Paula | Officer; SVP of Human Resources | Biological Products, (No Diagnostic Substances) | SALE | $43.79 | 297 | $13,005 | 124,104 | -0.2% |
| 2026-03-24 20:05 | 2026-03-20 | TWST | Twist Bioscience Corp | Leproust Emily M. | Director, Officer; Chief Executive Officer | Biological Products, (No Diagnostic Substances) | SALE | $43.79 | 1,742 | $76,276 | 858,887 | -0.2% |
| 2026-03-25 01:12 | 2026-03-24 | MGTX | MeiraGTx Holdings plc | Forbes Alexandria | Director, Officer; PRESIDENT & CEO | Biological Products, (No Diagnostic Substances) | SALE | $7.41 | 62,000 | $459,420 | 1,449,695 | -4.1% |
| 2026-03-25 01:15 | 2026-03-20 | RNXT | RenovoRx, Inc. | VOLL MARK | Officer; Chief Financial Officer | Pharmaceutical Preparations | BUY | $0.00 | 97,200 | $0 | 97,200 | +100.0% |
| 2026-03-25 01:16 | 2026-03-20 | RNXT | RenovoRx, Inc. | Bagai Shaun | Director, Officer; Chief Executive Officer | Pharmaceutical Preparations | BUY | $0.00 | 24,300 | $0 | 313,357 | +8.4% |
| 2026-03-25 01:16 | 2026-03-20 | RNXT | RenovoRx, Inc. | Marton Laurence | Director | Pharmaceutical Preparations | BUY | $0.00 | 9,720 | $0 | 9,720 | +100.0% |
| 2026-03-24 23:45 | 2026-03-23 | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | Officer; Chief Financial Officer | Pharmaceutical Preparations | OPT+S | $18.52 | 9,200 | $170,348 | 145,355 | -6.0% |
| 2026-03-24 23:24 | 2026-03-23 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Officer; Chief Scientific Officer | Pharmaceutical Preparations | OPT+S | $2.86 | 6,500 | $18,568 | 0 | -100.0% |
| 2026-03-24 22:56 | 2026-03-23 | OKUR | OnKure Therapeutics, Inc. | Leverone Jason A. | Officer; Chief Financial Officer | Pharmaceutical Preparations | SALE | $4.16 | 301 | $1,251 | 16,000 | -1.8% |
| 2026-03-24 22:57 | 2026-03-23 | OKUR | OnKure Therapeutics, Inc. | Saccomano Nicholas A | Director, Officer; President and CEO | Pharmaceutical Preparations | SALE | $4.16 | 86 | $357 | 7,333 | -1.2% |
| 2026-03-24 22:30 | 2026-03-20 | FDMT | 4D Molecular Therapeutics, Inc. | Gupta Ashoo | Officer; VP, Finance and Controller | Biological Products, (No Diagnostic Substances) | OPT+S | $8.61 | 390 | $3,358 | 47,055 | -0.8% |
| 2026-03-24 22:04 | 2026-03-23 | VTRS | Viatris Inc | Campbell Paul | Officer; See Remarks | Pharmaceutical Preparations | SALE | $13.28 | 21,350 | $283,539 | 366,288 | -5.5% |
| 2026-03-24 21:37 | 2026-03-23 | CRSP | CRISPR Therapeutics AG | Prasad Raju | Officer; Chief Financial Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $46.78 | 3,708 | $173,460 | 15,565 | -19.2% |
| 2026-03-24 21:37 | 2026-03-23 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | Director, Officer; Chief Executive Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $46.78 | 10,020 | $468,736 | 255,501 | -3.8% |
| 2026-03-24 21:38 | 2026-03-23 | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | Officer; General Counsel and Secretary | Biological Products, (No Diagnostic Substances) | OPT+S | $46.78 | 3,182 | $148,854 | 94,308 | -3.3% |
| 2026-03-24 21:05 | 2026-03-20 | TARS | Tarsus Pharmaceuticals, Inc. | Neervannan Seshadri | Officer; Chief Operating Officer | Biological Products, (No Diagnostic Substances) | SALE | $66.75 | 2,989 | $199,516 | 82,791 | -3.5% |
| 2026-03-24 20:54 | 2026-03-20 | CORT | CORCEPT THERAPEUTICS INC | Guyer William | Officer; Chief Development Officer | Pharmaceutical Preparations | OPT+S | $36.01 | 11,767 | $423,730 | 2,231 | -84.1% |
| 2026-03-24 20:31 | 2026-03-23 | UTHR | UNITED THERAPEUTICS Corp | Olian Judy D. | Director | Pharmaceutical Preparations | SALE | $530.00 | 200 | $106,000 | 4,245 | -4.5% |
| 2026-03-24 20:32 | 2026-03-23 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Pharmaceutical Preparations | OPT+S | $527.01 | 9,500 | $5,006,558 | 40,513 | -19.0% |
| 2026-03-24 20:33 | 2026-03-23 | UTHR | UNITED THERAPEUTICS Corp | EDGEMOND JAMES | Officer; CFO AND TREASURER | Pharmaceutical Preparations | OPT+S | $527.48 | 10,000 | $5,274,802 | 18,876 | -34.6% |
| 2026-03-23 20:05 | 2026-03-19 | ALXO | ALX ONCOLOGY HOLDINGS INC | Pinto Shelly | Officer; SVP, FINANCE AND CAO | Pharmaceutical Preparations | SALE | $2.17 | 903 | $1,960 | 86,805 | -1.0% |
| 2026-03-23 20:05 | 2026-03-19 | ALXO | ALX ONCOLOGY HOLDINGS INC | Lettmann Jason | Director, Officer; CHIEF EXECUTIVE OFFICER | Pharmaceutical Preparations | SALE | $2.17 | 12,311 | $26,715 | 293,609 | -4.0% |
| 2026-03-23 20:05 | 2026-03-20 | KLRS | Kalaris Therapeutics, Inc. | Hagen Brett R | Officer; Chief Accounting Officer | Biological Products, (No Diagnostic Substances) | SALE | $6.72 | 1,915 | $12,869 | 0 | -100.0% |
| 2026-03-24 01:23 | 2026-03-20 | IMNM | Immunome Inc. | WAGENHEIM PHILIP | Director | Pharmaceutical Preparations | SALE | $20.55 | 65,000 | $1,335,627 | 341,147 | -16.0% |
| 2026-03-23 23:36 | 2026-03-19 | IONS | IONIS PHARMACEUTICALS INC | Schneider Eugene | Officer; EVP, Chf Clinical Develop Ofcr | Pharmaceutical Preparations | SALE | $70.97 | 5,812 | $412,486 | 63,890 | -8.3% |
| 2026-03-23 23:18 | 2026-03-19 | ADPT | Adaptive Biotechnologies Corp | RUBINSTEIN JULIE | Officer; President and COO | Biological Products, (No Diagnostic Substances) | OPT+S | $13.46 | 57,180 | $769,643 | 481,906 | -10.6% |
| 2026-03-23 20:30 | 2026-03-20 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Pharmaceutical Preparations | OPT+S | $524.99 | 9,500 | $4,987,387 | 40,513 | -19.0% |
| 2026-03-23 11:30 | 2026-03-19 | IBIO | iBio, Inc. | Brenner Martin | Director, Officer; See Remarks | Pharmaceutical Preparations | BUY | $2.02 | 12,336 | $24,919 | 30,652 | +67.4% |
| 2026-03-23 11:31 | 2026-03-19 | IBIO | iBio, Inc. | Duran Felipe | Officer; Chief Financial Officer | Pharmaceutical Preparations | BUY | $2.02 | 24,835 | $50,132 | 35,974 | +223.0% |
| 2026-03-20 20:05 | 2026-03-18 | PVLA | PALVELLA THERAPEUTICS, INC. | Goin Kathleen | Officer; Chief Operating Officer | Pharmaceutical Preparations | OPT+S | $117.99 | 4,302 | $507,611 | 0 | -100.0% |
| 2026-03-20 20:25 | 2026-03-20 | OPK | OPKO HEALTH, INC. | PAGANELLI JOHN A | Director | Pharmaceutical Preparations | BUY | $1.14 | 10,000 | $11,350 | 394,340 | +2.6% |
| 2026-03-20 20:05 | 2026-03-19 | INSM | INSMED Inc | Lewis William | Director, Officer; Chair and CEO | Pharmaceutical Preparations | OPT+S | $143.52 | 10,699 | $1,535,542 | 301,185 | -3.4% |
| 2026-03-20 23:19 | 2026-03-20 | EOLS | Evolus, Inc. | MOATAZEDI DAVID | Director, Officer; See Remarks | Pharmaceutical Preparations | SALE | $4.75 | 13,669 | $64,929 | 604,700 | -2.2% |
| 2026-03-20 23:19 | 2026-03-20 | EOLS | Evolus, Inc. | Avelar Rui | Officer; See Remarks | Pharmaceutical Preparations | SALE | $4.75 | 3,119 | $14,815 | 427,423 | -0.7% |
| 2026-03-20 22:50 | 2026-03-20 | MAZE | Maze Therapeutics, Inc. | Bernstein Harold | Officer; President, R&D & CMO | Biological Products, (No Diagnostic Substances) | OPT+S | $49.10 | 15,000 | $736,440 | 0 | -100.0% |
| 2026-03-20 22:30 | 2026-03-20 | KYMR | Kymera Therapeutics, Inc. | Esposito Pamela | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $79.15 | 2,500 | $197,877 | 0 | -100.0% |
| 2026-03-20 21:14 | 2026-03-18 | COLL | COLLEGIUM PHARMACEUTICAL, INC | Dieter David | Officer; EVP & General Counsel | Pharmaceutical Preparations | SALE | $34.92 | 13,976 | $488,099 | 77,071 | -15.4% |
| 2026-03-20 20:53 | 2026-03-20 | USNA | USANA HEALTH SCIENCES INC | FULLER GILBERT A | Director | Medicinal Chemicals & Botanical Products | SALE | $17.00 | 1,058 | $17,986 | 0 | -100.0% |
Strategic Signal Filtering
Our screener allows you to cut through the noise of routine stock grants and small trades. By focusing on high-value transactions from C-suite executives (CEO/CFO), you can identify where the "Smart Money" is being deployed with maximum conviction.
Investing Without Illusions
Insider data is not a magic wand, but it is the most honest indicator available. While insiders sell for many reasons (taxes, personal needs), they generally buy for only one: they believe the stock price is undervalued. We provide the tools to track these skin-in-the-game moves.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.